BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...programAstellas Pharma Inc. (Tokyo:4503) discontinued its TIGIT antagonist ASP8374 (PTZ-201) that it gained after acquiring Potenza Therapeutics Inc....
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...platform developer Xyphos Biosciences Inc. for $120 million and exercised an option to take out Potenza Therapeutics Inc....
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...pipeline since then. It gained two Phase I programs through its December 2018 acquisition of Potenza Therapeutics Inc....
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...who is also an executive partner at MPM, previously served as president and CEO of Potenza Therapeutics Inc....
BioCentury | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

...exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics...
...Potenza Therapeutics Inc., Cambridge, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Shannon Lehnbeuter ASP8374, PTZ-201 GITR agonist PTZ-329 Astellas Pharma Inc. Potenza Therapeutics Inc. Neuropilin...
BioCentury | Jul 12, 2018
Translation in Brief

Reviving NK cells

...Pharmaceuticals Inc. (NASDAQ:OMED) has OMP-313M32 in Phase I testing; and Astellas Pharma Inc. (Tokyo:4503) and Potenza Therapeutics Inc....
BioCentury | Jan 6, 2017
Company News

Abzena, Trieza deal

...products containing the sequence. Trieza is a start-up formed last quarter as a spinout from Potenza Therapeutics Inc....
BioCentury | May 23, 2016
Finance

Venturing west

...The build-to-buys include Mitobridge Inc. , which develops therapeutics that affect mitochondrial function, immuno-oncology play Potenza Therapeutics Inc....
BioCentury | May 18, 2015
Financial News

MPM Capital financial update

...new fund. They include encapsulated cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.); cancer plays Potenza Therapeutics Inc....
BioCentury | May 18, 2015
Finance

New (Bio)ventures at MPM

...Astellas also has a build-to-buy deal with a portfolio company from BioVentures 2014, immuno-oncology play Potenza Therapeutics Inc....
Items per page:
1 - 10 of 13
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...programAstellas Pharma Inc. (Tokyo:4503) discontinued its TIGIT antagonist ASP8374 (PTZ-201) that it gained after acquiring Potenza Therapeutics Inc....
BioCentury | Mar 24, 2020
Deals

With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017

...platform developer Xyphos Biosciences Inc. for $120 million and exercised an option to take out Potenza Therapeutics Inc....
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

...pipeline since then. It gained two Phase I programs through its December 2018 acquisition of Potenza Therapeutics Inc....
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...who is also an executive partner at MPM, previously served as president and CEO of Potenza Therapeutics Inc....
BioCentury | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

...exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics...
...Potenza Therapeutics Inc., Cambridge, Mass. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Shannon Lehnbeuter ASP8374, PTZ-201 GITR agonist PTZ-329 Astellas Pharma Inc. Potenza Therapeutics Inc. Neuropilin...
BioCentury | Jul 12, 2018
Translation in Brief

Reviving NK cells

...Pharmaceuticals Inc. (NASDAQ:OMED) has OMP-313M32 in Phase I testing; and Astellas Pharma Inc. (Tokyo:4503) and Potenza Therapeutics Inc....
BioCentury | Jan 6, 2017
Company News

Abzena, Trieza deal

...products containing the sequence. Trieza is a start-up formed last quarter as a spinout from Potenza Therapeutics Inc....
BioCentury | May 23, 2016
Finance

Venturing west

...The build-to-buys include Mitobridge Inc. , which develops therapeutics that affect mitochondrial function, immuno-oncology play Potenza Therapeutics Inc....
BioCentury | May 18, 2015
Financial News

MPM Capital financial update

...new fund. They include encapsulated cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.); cancer plays Potenza Therapeutics Inc....
BioCentury | May 18, 2015
Finance

New (Bio)ventures at MPM

...Astellas also has a build-to-buy deal with a portfolio company from BioVentures 2014, immuno-oncology play Potenza Therapeutics Inc....
Items per page:
1 - 10 of 13